Patrick Griffin soars in as ImmusanT CMO
This article was originally published in Scrip
Privately-held biotech ImmusanT has hired Dr Patrick Griffin chief medical officer and senior vice-president of development. Dr Griffin joins ImmusanT from Sanofi's immuno-inflammation therapeutic strategy unit where he was most recently head of external innovation. He originally joined Sanofi in 2005 as senior director of clinical development.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.